Eisai (OTCMKTS:ESALY) Trading Down 2.7%

Eisai Co., Ltd (OTCMKTS:ESALY) shares fell 2.7% during trading on Wednesday . The stock traded as low as $70.24 and last traded at $70.73, 12,263 shares changed hands during mid-day trading. An increase of 131% from the average session volume of 5,299 shares. The stock had previously closed at $72.73.

Several equities research analysts have recently issued reports on ESALY shares. Jefferies Financial Group assumed coverage on Eisai in a research report on Tuesday, September 24th. They issued a “buy” rating on the stock. Daiwa Capital Markets downgraded Eisai from a “neutral” rating to a “sell” rating in a research note on Tuesday, September 17th. Finally, Zacks Investment Research raised Eisai from a “hold” rating to a “strong-buy” rating and set a $79.00 price target on the stock in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $79.00.

The company has a current ratio of 1.91, a quick ratio of 1.66 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $21.29 billion, a P/E ratio of 35.54, a P/E/G ratio of 2.27 and a beta of 0.38. The company has a 50 day simple moving average of $67.63 and a two-hundred day simple moving average of $57.48.

Eisai (OTCMKTS:ESALY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.42). Eisai had a return on equity of 9.07% and a net margin of 9.10%. The firm had revenue of $1.35 billion for the quarter. On average, sell-side analysts expect that Eisai Co., Ltd will post 2.59 EPS for the current fiscal year.

About Eisai (OTCMKTS:ESALY)

Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.

Featured Article: How to Use a Moving Average for Trading 

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.